Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors

Zahraa Al-Hilli, Judy C Boughey, Tanya L. Hoskin, Courtney N. Heins, Tina J Hieken

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Use of targeted therapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer has led to improvements in survival. Furthermore, neoadjuvant chemotherapy (NAC) with dual HER2 agents demonstrated improved pathological complete response (pCR) rates. With these data, and with US FDA approval in September 2013 of pertuzumab in the neoadjuvant setting, we hypothesized that the use of NAC for early-stage HER2-positive patients is increasing. Methods: With Institutional Review Board approval, we reviewed 267 patients with 268 clinical T1 and T2 HER2-positive tumors treated from October 2008 to September 2014. We compared treatment in the early (October 2008–September 2013) to recent (October 2013–September 2014) periods. Statistical analysis was performed using Chi square tests. Results: Mean patient age was 59 years. Clinical T stage included 6 (2 %) T1mic, 11 (4 %) T1a, 41 (15 %) T1b, 95 (35 %) T1c, and 115 (43 %) T2. Targeted therapy included combinations of trastuzumab, lapatinib, pertuzumab, and neratinib. NAC use increased from 53/219 (24.2 %) in the early group to 19/49 (38.8 %) in the recent group (p = 0.04). Forty-two percent (8/19) of patients in the recent group received neoadjuvant pertuzumab versus 0/53 in the early group (p < 0.0001). More clinically node-negative (cN0) patients received NAC in the recent (12/41, 29.3 %) versus early (20/167, 12.0 %) period (p = 0.01). For T1 tumors, the use of NAC more than doubled between the two time periods (5.6–17.2 %; p = 0.06), while NAC use increased from 48 to 70 % for T2 tumors (p = 0.08). The overall pCR rate after NAC was 48.6 % (35/72). Conclusions: NAC for HER2-positive breast cancer patients is increasing. Most striking was a substantial increase in NAC for patients with T1 tumors and cN0 disease.

Original languageEnglish (US)
Pages (from-to)3369-3375
Number of pages7
JournalAnnals of Surgical Oncology
Volume22
Issue number10
DOIs
StatePublished - Jul 23 2015

Fingerprint

Neoadjuvant Therapy
Drug Therapy
Neoplasms
Breast Neoplasms
human ERBB2 protein
Research Ethics Committees
Chi-Square Distribution
Therapeutics
Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors. / Al-Hilli, Zahraa; Boughey, Judy C; Hoskin, Tanya L.; Heins, Courtney N.; Hieken, Tina J.

In: Annals of Surgical Oncology, Vol. 22, No. 10, 23.07.2015, p. 3369-3375.

Research output: Contribution to journalArticle

Al-Hilli, Zahraa ; Boughey, Judy C ; Hoskin, Tanya L. ; Heins, Courtney N. ; Hieken, Tina J. / Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors. In: Annals of Surgical Oncology. 2015 ; Vol. 22, No. 10. pp. 3369-3375.
@article{8ece2736cdb04c28a08bb3401fa5d9af,
title = "Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors",
abstract = "Background: Use of targeted therapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer has led to improvements in survival. Furthermore, neoadjuvant chemotherapy (NAC) with dual HER2 agents demonstrated improved pathological complete response (pCR) rates. With these data, and with US FDA approval in September 2013 of pertuzumab in the neoadjuvant setting, we hypothesized that the use of NAC for early-stage HER2-positive patients is increasing. Methods: With Institutional Review Board approval, we reviewed 267 patients with 268 clinical T1 and T2 HER2-positive tumors treated from October 2008 to September 2014. We compared treatment in the early (October 2008–September 2013) to recent (October 2013–September 2014) periods. Statistical analysis was performed using Chi square tests. Results: Mean patient age was 59 years. Clinical T stage included 6 (2 {\%}) T1mic, 11 (4 {\%}) T1a, 41 (15 {\%}) T1b, 95 (35 {\%}) T1c, and 115 (43 {\%}) T2. Targeted therapy included combinations of trastuzumab, lapatinib, pertuzumab, and neratinib. NAC use increased from 53/219 (24.2 {\%}) in the early group to 19/49 (38.8 {\%}) in the recent group (p = 0.04). Forty-two percent (8/19) of patients in the recent group received neoadjuvant pertuzumab versus 0/53 in the early group (p < 0.0001). More clinically node-negative (cN0) patients received NAC in the recent (12/41, 29.3 {\%}) versus early (20/167, 12.0 {\%}) period (p = 0.01). For T1 tumors, the use of NAC more than doubled between the two time periods (5.6–17.2 {\%}; p = 0.06), while NAC use increased from 48 to 70 {\%} for T2 tumors (p = 0.08). The overall pCR rate after NAC was 48.6 {\%} (35/72). Conclusions: NAC for HER2-positive breast cancer patients is increasing. Most striking was a substantial increase in NAC for patients with T1 tumors and cN0 disease.",
author = "Zahraa Al-Hilli and Boughey, {Judy C} and Hoskin, {Tanya L.} and Heins, {Courtney N.} and Hieken, {Tina J}",
year = "2015",
month = "7",
day = "23",
doi = "10.1245/s10434-015-4718-6",
language = "English (US)",
volume = "22",
pages = "3369--3375",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors

AU - Al-Hilli, Zahraa

AU - Boughey, Judy C

AU - Hoskin, Tanya L.

AU - Heins, Courtney N.

AU - Hieken, Tina J

PY - 2015/7/23

Y1 - 2015/7/23

N2 - Background: Use of targeted therapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer has led to improvements in survival. Furthermore, neoadjuvant chemotherapy (NAC) with dual HER2 agents demonstrated improved pathological complete response (pCR) rates. With these data, and with US FDA approval in September 2013 of pertuzumab in the neoadjuvant setting, we hypothesized that the use of NAC for early-stage HER2-positive patients is increasing. Methods: With Institutional Review Board approval, we reviewed 267 patients with 268 clinical T1 and T2 HER2-positive tumors treated from October 2008 to September 2014. We compared treatment in the early (October 2008–September 2013) to recent (October 2013–September 2014) periods. Statistical analysis was performed using Chi square tests. Results: Mean patient age was 59 years. Clinical T stage included 6 (2 %) T1mic, 11 (4 %) T1a, 41 (15 %) T1b, 95 (35 %) T1c, and 115 (43 %) T2. Targeted therapy included combinations of trastuzumab, lapatinib, pertuzumab, and neratinib. NAC use increased from 53/219 (24.2 %) in the early group to 19/49 (38.8 %) in the recent group (p = 0.04). Forty-two percent (8/19) of patients in the recent group received neoadjuvant pertuzumab versus 0/53 in the early group (p < 0.0001). More clinically node-negative (cN0) patients received NAC in the recent (12/41, 29.3 %) versus early (20/167, 12.0 %) period (p = 0.01). For T1 tumors, the use of NAC more than doubled between the two time periods (5.6–17.2 %; p = 0.06), while NAC use increased from 48 to 70 % for T2 tumors (p = 0.08). The overall pCR rate after NAC was 48.6 % (35/72). Conclusions: NAC for HER2-positive breast cancer patients is increasing. Most striking was a substantial increase in NAC for patients with T1 tumors and cN0 disease.

AB - Background: Use of targeted therapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer has led to improvements in survival. Furthermore, neoadjuvant chemotherapy (NAC) with dual HER2 agents demonstrated improved pathological complete response (pCR) rates. With these data, and with US FDA approval in September 2013 of pertuzumab in the neoadjuvant setting, we hypothesized that the use of NAC for early-stage HER2-positive patients is increasing. Methods: With Institutional Review Board approval, we reviewed 267 patients with 268 clinical T1 and T2 HER2-positive tumors treated from October 2008 to September 2014. We compared treatment in the early (October 2008–September 2013) to recent (October 2013–September 2014) periods. Statistical analysis was performed using Chi square tests. Results: Mean patient age was 59 years. Clinical T stage included 6 (2 %) T1mic, 11 (4 %) T1a, 41 (15 %) T1b, 95 (35 %) T1c, and 115 (43 %) T2. Targeted therapy included combinations of trastuzumab, lapatinib, pertuzumab, and neratinib. NAC use increased from 53/219 (24.2 %) in the early group to 19/49 (38.8 %) in the recent group (p = 0.04). Forty-two percent (8/19) of patients in the recent group received neoadjuvant pertuzumab versus 0/53 in the early group (p < 0.0001). More clinically node-negative (cN0) patients received NAC in the recent (12/41, 29.3 %) versus early (20/167, 12.0 %) period (p = 0.01). For T1 tumors, the use of NAC more than doubled between the two time periods (5.6–17.2 %; p = 0.06), while NAC use increased from 48 to 70 % for T2 tumors (p = 0.08). The overall pCR rate after NAC was 48.6 % (35/72). Conclusions: NAC for HER2-positive breast cancer patients is increasing. Most striking was a substantial increase in NAC for patients with T1 tumors and cN0 disease.

UR - http://www.scopus.com/inward/record.url?scp=84940451482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940451482&partnerID=8YFLogxK

U2 - 10.1245/s10434-015-4718-6

DO - 10.1245/s10434-015-4718-6

M3 - Article

C2 - 26202564

AN - SCOPUS:84940451482

VL - 22

SP - 3369

EP - 3375

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 10

ER -